{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T21:06:02Z","timestamp":1790456762927,"version":"4.1.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2015,2,10]],"date-time":"2015-02-10T00:00:00Z","timestamp":1423526400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.1007\/s00280-015-2695-x","type":"journal-article","created":{"date-parts":[[2015,2,9]],"date-time":"2015-02-09T11:35:40Z","timestamp":1423481740000},"page":"869-874","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Phase I trial of valproic acid and lenalidomide in patients with advanced cancer"],"prefix":"10.1007","volume":"75","author":[{"given":"Mehmet Asim","family":"Bilen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siqing","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald S.","family":"Falchook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaan S.","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer J.","family":"Wheler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maen","family":"Abdelrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Basak","family":"Erguvan-Dogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S.","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Apostolia M.","family":"Tsimberidou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Razelle","family":"Kurzrock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aung","family":"Naing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,2,10]]},"reference":[{"key":"2695_CR1","doi-asserted-by":"crossref","unstructured":"Linde M, Mulleners WM, Chronicle EP, McCrory DC (2013) Valproate (valproic acid or sodium valproate or a combination of the two) for the prophylaxis of episodic migraine in adults. The Cochrane database of systematic reviews 6:CD010611. doi: 10.1002\/14651858.CD010611","DOI":"10.1002\/14651858.CD010611"},{"issue":"1","key":"2695_CR2","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1124\/pr.111.005512","volume":"65","author":"CT Chiu","year":"2013","unstructured":"Chiu CT, Wang Z, Hunsberger JG, Chuang DM (2013) Therapeutic potential of mood stabilizers lithium and valproic acid: beyond bipolar disorder. Pharmacol Rev 65(1):105\u2013142. doi: 10.1124\/pr.111.005512","journal-title":"Pharmacol Rev"},{"key":"2695_CR3","doi-asserted-by":"crossref","unstructured":"Schwarz C, Volz A, Li C, Leucht S (2008) Valproate for schizophrenia. The Cochrane database of systematic reviews 3:CD004028. doi: 10.1002\/14651858.CD004028.pub3","DOI":"10.1002\/14651858.CD004028.pub3"},{"issue":"5","key":"2695_CR4","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1517\/17425250902911455","volume":"5","author":"PM Haddad","year":"2009","unstructured":"Haddad PM, Das A, Ashfaq M, Wieck A (2009) A review of valproate in psychiatric practice. Expert opin drug metabg toxicol 5(5):539\u2013551. doi: 10.1517\/17425250902911455","journal-title":"Expert opin drug metabg toxicol"},{"issue":"39","key":"2695_CR5","doi-asserted-by":"crossref","first-page":"36734","DOI":"10.1074\/jbc.M101287200","volume":"276","author":"CJ Phiel","year":"2001","unstructured":"Phiel CJ, Zhang F, Huang EY, Guenther MG, Lazar MA, Klein PS (2001) Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem 276(39):36734\u201336741. doi: 10.1074\/jbc.M101287200","journal-title":"J Biol Chem"},{"issue":"5","key":"2695_CR6","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1002\/med.10017","volume":"22","author":"RA Blaheta","year":"2002","unstructured":"Blaheta RA, Cinatl J Jr (2002) Anti-tumor mechanisms of valproate: a novel role for an old drug. Med Res Rev 22(5):492\u2013511. doi: 10.1002\/med.10017","journal-title":"Med Res Rev"},{"issue":"9","key":"2695_CR7","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1517\/13543784.2012.694425","volume":"21","author":"S Berendsen","year":"2012","unstructured":"Berendsen S, Broekman M, Seute T, Snijders T, van Es C, de Vos F, Regli L, Robe P (2012) Valproic acid for the treatment of malignant gliomas: review of the preclinical rationale and published clinical results. Expert Opin Investig Drugs 21(9):1391\u20131415. doi: 10.1517\/13543784.2012.694425","journal-title":"Expert Opin Investig Drugs"},{"issue":"4","key":"2695_CR8","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1002\/med.20027","volume":"25","author":"RA Blaheta","year":"2005","unstructured":"Blaheta RA, Michaelis M, Driever PH, Cinatl J Jr (2005) Evolving anticancer drug valproic acid: insights into the mechanism and clinical studies. Med Res Rev 25(4):383\u2013397. doi: 10.1002\/med.20027","journal-title":"Med Res Rev"},{"key":"2695_CR9","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1756-8722-3-5","volume":"3","author":"J Tan","year":"2010","unstructured":"Tan J, Cang S, Ma Y, Petrillo RL, Liu D (2010) Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents. J Hematol oncol 3:5. doi: 10.1186\/1756-8722-3-5","journal-title":"J Hematol oncol"},{"issue":"3","key":"2695_CR10","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1210\/jc.2004-1355","volume":"90","author":"MG Catalano","year":"2005","unstructured":"Catalano MG, Fortunati N, Pugliese M, Costantino L, Poli R, Bosco O, Boccuzzi G (2005) Valproic acid induces apoptosis and cell cycle arrest in poorly differentiated thyroid cancer cells. J Clin Endocrinol Metab 90(3):1383\u20131389. doi: 10.1210\/jc.2004-1355","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2695_CR11","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1158\/1078-0432.CCR-03-0100","volume":"10","author":"N Takai","year":"2004","unstructured":"Takai N, Desmond JC, Kumagai T, Gui D, Said JW, Whittaker S, Miyakawa I, Koeffler HP (2004) Histone deacetylase inhibitors have a profound antigrowth activity in endometrial cancer cells. Clin Cancer Res 10(3):1141\u20131149","journal-title":"Clin Cancer Res"},{"issue":"12","key":"2695_CR12","doi-asserted-by":"crossref","first-page":"2760","DOI":"10.1002\/cncr.20709","volume":"101","author":"N Takai","year":"2004","unstructured":"Takai N, Kawamata N, Gui D, Said JW, Miyakawa I, Koeffler HP (2004) Human ovarian carcinoma cells: histone deacetylase inhibitors exhibit antiproliferative activity and potently induce apoptosis. Cancer 101(12):2760\u20132770. doi: 10.1002\/cncr.20709","journal-title":"Cancer"},{"issue":"5","key":"2695_CR13","first-page":"1233","volume":"28","author":"T Sato","year":"2006","unstructured":"Sato T, Suzuki M, Sato Y, Echigo S, Rikiishi H (2006) Sequence-dependent interaction between cisplatin and histone deacetylase inhibitors in human oral squamous cell carcinoma cells. Int J Oncol 28(5):1233\u20131241","journal-title":"Int J Oncol"},{"key":"2695_CR14","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1475-2867-6-2","volume":"6","author":"A Chavez-Blanco","year":"2006","unstructured":"Chavez-Blanco A, Perez-Plasencia C, Perez-Cardenas E, Carrasco-Legleu C, Rangel-Lopez E, Segura-Pacheco B, Taja-Chayeb L, Trejo-Becerril C, Gonzalez-Fierro A, Candelaria M, Cabrera G, Duenas-Gonzalez A (2006) Antineoplastic effects of the DNA methylation inhibitor hydralazine and the histone deacetylase inhibitor valproic acid in cancer cell lines. Cancer Cell Int 6:2. doi: 10.1186\/1475-2867-6-2","journal-title":"Cancer Cell Int"},{"issue":"1\u20132","key":"2695_CR15","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.mvr.2005.01.002","volume":"69","author":"K Dredge","year":"2005","unstructured":"Dredge K, Horsfall R, Robinson SP, Zhang LH, Lu L, Tang Y, Shirley MA, Muller G, Schafer P, Stirling D, Dalgleish AG, Bartlett JB (2005) Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro. Microvasc Res 69(1\u20132):56\u201363. doi: 10.1016\/j.mvr.2005.01.002","journal-title":"Microvasc Res"},{"issue":"2","key":"2695_CR16","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1158\/0008-5472.CAN-06-2317","volume":"67","author":"D Verhelle","year":"2007","unstructured":"Verhelle D, Corral LG, Wong K, Mueller JH, Moutouh-de Parseval L, Jensen-Pergakes K, Schafer PH, Chen R, Glezer E, Ferguson GD, Lopez-Girona A, Muller GW, Brady HA, Chan KW (2007) Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+progenitor cells. Cancer Res 67(2):746\u2013755. doi: 10.1158\/0008-5472.CAN-06-2317","journal-title":"Cancer Res"},{"issue":"1","key":"2695_CR17","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/j.1365-2141.2007.06841.x","volume":"140","author":"N Reddy","year":"2008","unstructured":"Reddy N, Hernandez-Ilizaliturri FJ, Deeb G, Roth M, Vaughn M, Knight J, Wallace P, Czuczman MS (2008) Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo. Br J Haematol 140(1):36\u201345. doi: 10.1111\/j.1365-2141.2007.06841.x","journal-title":"Br J Haematol"},{"issue":"10","key":"2695_CR18","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1038\/sj.bjc.6600607","volume":"87","author":"K Dredge","year":"2002","unstructured":"Dredge K, Marriott JB, Macdonald CD, Man HW, Chen R, Muller GW, Stirling D, Dalgleish AG (2002) Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects. Br J Cancer 87(10):1166\u20131172. doi: 10.1038\/sj.bjc.6600607","journal-title":"Br J Cancer"},{"issue":"1","key":"2695_CR19","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1182\/blood.V98.1.210","volume":"98","author":"FE Davies","year":"2001","unstructured":"Davies FE, Raje N, Hideshima T, Lentzsch S, Young G, Tai YT, Lin B, Podar K, Gupta D, Chauhan D, Treon SP, Richardson PG, Schlossman RL, Morgan GJ, Muller GW, Stirling DI, Anderson KC (2001) Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 98(1):210\u2013216","journal-title":"Blood"},{"issue":"3","key":"2695_CR20","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92(3):205\u2013216","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"2695_CR21","doi-asserted-by":"crossref","first-page":"78","DOI":"10.6004\/jnccn.2006.0008","volume":"4","author":"A Naing","year":"2006","unstructured":"Naing A, Sokol L, List AF (2006) Developmental therapeutics for myelodysplastic syndromes. J Natl Compr Cancer Netw 4(1):78\u201382","journal-title":"J Natl Compr Cancer Netw"},{"key":"2695_CR22","author":"P Ganesan","year":"2013","unstructured":"Ganesan P, Piha-Paul S, Naing A, Falchook G, Wheler J, Fu S, Hong DS, Kurzrock R, Janku F, Laday S, Bedikian AY, Kies M, Wolff RA, Tsimberidou AM (2013) Phase I clinical trial of lenalidomide in combination with sorafenib in patients with advanced cancer. Invest New Drugs. doi: 10.1007\/s10637-013-9966-3","journal-title":"Invest New Drugs"},{"issue":"6","key":"2695_CR23","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1007\/s10637-013-0013-1","volume":"31","author":"P Ganesan","year":"2013","unstructured":"Ganesan P, Piha-Paul S, Naing A, Falchook G, Wheler J, Janku F, Zinner R, Laday S, Kies M, Tsimberidou AM (2013) Phase I clinical trial of lenalidomide in combination with temsirolimus in patients with advanced cancer. Invest New Drugs 31(6):1505\u20131513. doi: 10.1007\/s10637-013-0013-1","journal-title":"Invest New Drugs"},{"issue":"2","key":"2695_CR24","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/01.nrl.0000051445.03160.2e","volume":"9","author":"JN Gaitanis","year":"2003","unstructured":"Gaitanis JN, Drislane FW (2003) Status epilepticus: a review of different syndromes, their current evaluation, and treatment. Neurologist 9(2):61\u201376. doi: 10.1097\/01.nrl.0000051445.03160.2e","journal-title":"Neurologist"},{"issue":"9","key":"2695_CR25","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1182\/blood-2002-03-0996","volume":"100","author":"PG Richardson","year":"2002","unstructured":"Richardson PG, Schlossman RL, Weller E, Hideshima T, Mitsiades C, Davies F, LeBlanc R, Catley LP, Doss D, Kelly K, McKenney M, Mechlowicz J, Freeman A, Deocampo R, Rich R, Ryoo JJ, Chauhan D, Balinski K, Zeldis J, Anderson KC (2002) Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 100(9):3063\u20133067. doi: 10.1182\/blood-2002-03-0996","journal-title":"Blood"},{"key":"2695_CR26","doi-asserted-by":"crossref","unstructured":"Zonder JA (2006) Thrombotic complications of myeloma therapy. Hematology Am Soc Hematol Educ Prog:348\u2013355. doi: 10.1182\/asheducation-2006.1.348","DOI":"10.1182\/asheducation-2006.1.348"},{"issue":"5","key":"2695_CR27","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/S0002-9610(97)00153-0","volume":"174","author":"RH Spiro","year":"1997","unstructured":"Spiro RH (1997) Distant metastasis in adenoid cystic carcinoma of salivary origin. Am J Surg 174(5):495\u2013498","journal-title":"Am J Surg"},{"issue":"3","key":"2695_CR28","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1002\/hed.20327","volume":"28","author":"J Gilbert","year":"2006","unstructured":"Gilbert J, Li Y, Pinto HA, Jennings T, Kies MS, Silverman P, Forastiere AA (2006) Phase II trial of taxol in salivary gland malignancies (E1394): a trial of the eastern cooperative oncology group. Head Neck 28(3):197\u2013204. doi: 10.1002\/hed.20327","journal-title":"Head Neck"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-015-2695-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-015-2695-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-015-2695-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,7]],"date-time":"2024-06-07T03:43:17Z","timestamp":1717731797000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-015-2695-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2,10]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["2695"],"URL":"https:\/\/doi.org\/10.1007\/s00280-015-2695-x","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,2,10]]}}}